All In Biotech

NDA 018671 · Cardinal Health 418

Sodium Iodide I 123

Sodium Iodide I-123 · Oral

Last checked: Nov 19, 2026Latest source record: Jun 13, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

May 27, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

28

5 Phase 3, 3 recruiting

FAERS reports

940

896 serious, 45 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 17, 2018.

INDICATION AND USE Administration of Sodium Iodide I 123 is indicated as a diagnostic procedure to be used in evaluating thyroid function and/or morphology.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • SODIUM IODIDE I 123 · SODIUM IODIDE I-123 200uCi · CAPSULE, ORAL · Prescription · TE AA
  • SODIUM IODIDE I 123 · SODIUM IODIDE I-123 400uCi · CAPSULE, ORAL · Discontinued
  • SODIUM IODIDE I 123 · SODIUM IODIDE I-123 100uCi · CAPSULE, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Iodide I-123" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypothyroidism384
  • endocrine ophthalmopathy36
  • treatment failure26
  • acute myeloid leukaemia24
  • dacryostenosis acquired24
  • parathyroid tumour benign21
  • abortion spontaneous20
  • hyperthyroidism20
  • hyperparathyroidism19
  • lacrimation increased19
  • breast cancer17
  • maternal exposure during pregnancy17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20061
200733
200876
200956
201056
2011263
2012173
201382
201414
201517
201613
20175
201826
201948
202013
202148
20228
20243
20251
20263

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Cardinal Health 418

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.